Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;7(4):355-365.
doi: 10.1007/s40472-020-00304-z. Epub 2020 Oct 21.

Antivirals for COVID-19 in Solid Organ Transplant Recipients

Justin C Laracy  1 , Elizabeth C Verna  2 , Marcus R Pereira  1
Affiliations
Review

Antivirals for COVID-19 in Solid Organ Transplant Recipients

Justin C Laracy et al. Curr Transplant Rep. 2020.

Abstract

Purpose of review: To evaluate the critical studies published so far on the most promising antiviral therapies for COVID-19, with particular emphasis on any solid organ transplant-specific information.

Recent findings: Although the literature is increasing exponentially, most clinical trials have been preliminary, thus lacking robust evidence to support many of the drugs discussed here. The main exception is remdesivir, for which several trials have been published supporting its use for patients with severe COVID-19. No solid organ transplant-specific data on remdesivir or other antiviral therapies have been published so far.

Summary: While further studies are urgently needed, in particular those specific to solid organ transplant recipients, the evidence so far only supports the use of remdesivir for patients with severe COVID-19.

Keywords: COVID-19; Convalescent plasma; Remdesivir; SARS-CoV-2; Solid organ transplant.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestECV is on the Gilead Advisory Board. MRP and JCL have no conflicts to declare.

Figures

Fig. 1
Fig. 1
COVID-19 disease progression
See this image and copyright information in PMC

References

    1. Coronavirus disease (COVID-19). Accessed July 6, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj...
    1. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706–711. doi: 10.1007/s11427-020-1661-4. - DOI - PMC - PubMed
    1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA Published online April 22, 2020. 2020. 10.1001/jama.2020.6775. - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–1776. doi: 10.1001/jama.2020.4683. - DOI - PubMed

LinkOut - more resources